Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

pembrolizumab 84Specimen Handling 79Carboplatin 74Magnetic Resonance Spectroscopy 71Biopsy 58Nivolumab 55Cisplatin 55Paclitaxel 46Cyclophosphamide 44durvalumab 37Radiotherapy 36Radiation 35Rituximab 34olaparib 33Etoposide 33Dexamethasone 33Ipilimumab 30Gemcitabine 30Lenalidomide 28Taxes 27Pemetrexed 27Doxorubicin 27Docetaxel 27Bevacizumab 24Prednisone 23Cytarabine 23X-Rays 22Trastuzumab 21cabozantinib 20Disulfides 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Has results × LFB-R603 × Clear all
NCT04624633 2026-02-25

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
29 enrolled 9 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04783415 2024-12-02

Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

City of Hope Medical Center

Phase 2 Active not recruiting
12 enrolled 8 charts
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡